孤儿药再探讨。 - Suppr

Orphan drugs revisited.

作者信息

McCabe C, Tsuchiya A, Claxton K, Raftery J

机构信息

Health Economics and Decision Science, School of Health and Related Research, Regent Court, 30 Regent Street, Sheffield S1 4DA.

出版信息

QJM. 2006 May;99(5):341-5; discussion 350-1. doi: 10.1093/qjmed/hcl033. Epub 2006 Feb 27.

DOI:10.1093/qjmed/hcl033

PMID:16504983

Abstract

摘要

相似文献

Orphan drugs revisited.

QJM. 2006 May;99(5):341-5; discussion 350-1. doi: 10.1093/qjmed/hcl033. Epub 2006 Feb 27.

The challenges of orphan drugs and orphan diseases: real and imagined.

Clin Pharmacol Ther. 2012 Aug;92(2):151-3. doi: 10.1038/clpt.2012.72.

EU to review rare disease drugs market exclusivity.

Nat Biotechnol. 2004 Sep;22(9):1061. doi: 10.1038/nbt0904-1061.

Management of rare diseases.

QJM. 2006 Feb;99(2):123-4. doi: 10.1093/qjmed/hcl006. Epub 2006 Jan 20.

Drugs for rare diseases: mixed assessment in Europe.

Prescrire Int. 2007 Feb;16(87):36-42.

Lucrative niches: how drugs for rare diseases became lifeline for companies.

Wall St J (East Ed). 2005 Nov 15:A1, A18.

[Orphan drugs: availability, reliability and reimbursement].

Ned Tijdschr Geneeskd. 2012;156(17):A4252.

Law and research could add up to profitable niche drugs.

Nature. 2007 Apr 19;446(7138):856. doi: 10.1038/446856b.

The European rare diseases therapeutic initiative.

PLoS Med. 2005 Sep;2(9):e243. doi: 10.1371/journal.pmed.0020243. Epub 2005 Aug 23.

A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.

J Med Ethics. 2012 Mar;38(3):148-53. doi: 10.1136/medethics-2011-100094. Epub 2011 Sep 24.

引用本文的文献

Debates over orphan drug pricing: a meta-narrative literature review.

Orphanet J Rare Dis. 2025 Mar 7;20(1):107. doi: 10.1186/s13023-025-03634-2.

Systematic Literature Review of Access Pathways to Drugs for Patients with Rare Diseases.

Appl Health Econ Health Policy. 2025 Mar;23(2):209-229. doi: 10.1007/s40258-024-00939-4. Epub 2024 Dec 28.

Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.

Front Pharmacol. 2022 Jan 21;12:750742. doi: 10.3389/fphar.2021.750742. eCollection 2021.

A systematic review of moral reasons on orphan drug reimbursement.

Orphanet J Rare Dis. 2021 Jun 30;16(1):292. doi: 10.1186/s13023-021-01925-y.

How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.

Front Pharmacol. 2021 May 12;12:631527. doi: 10.3389/fphar.2021.631527. eCollection 2021.

Why We Don't Need "Unmet Needs"! On the Concepts of Unmet Need and Severity in Health-Care Priority Setting.

Health Care Anal. 2019 Mar;27(1):26-44. doi: 10.1007/s10728-018-0361-2.

Orphan Drug Pricing: An Original Exponential Model Relating Price to the Number of Patients.

Sci Pharm. 2016 Jan 24;84(4):618-624. doi: 10.3390/scipharm84040618.

The (Ir)relevance of Group Size in Health Care Priority Setting: A Reply to Juth.

Health Care Anal. 2017 Mar;25(1):21-33. doi: 10.1007/s10728-016-0333-3.

Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.

Orphanet J Rare Dis. 2016 Jun 4;11(1):72. doi: 10.1186/s13023-016-0455-6.

Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.

Orphanet J Rare Dis. 2015 May 3;10:53. doi: 10.1186/s13023-015-0269-y.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Orphan drugs revisited.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献